---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000087"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-07-13T23:59:59+00:00"
generated_at: "2026-06-13T08:45:13.435616+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CB-010 Phase 1 data: 94% ORR, 69% CR in r/r B-NHL; 44% CR ≥6 months; cash ~$292.5M

## Summary
- CB-010 achieved 94% ORR (15/16) and 69% CR (11/16) in r/r B-NHL patients in ANTLER Phase 1 dose escalation.
- 44% of patients (7/16) had CR at ≥6 months; longest CR maintained at 24 months.
- LBCL subgroup (N=10): 90% ORR, 70% CR, 50% CR at ≥6 months; longest CR 18 months.
- CB-010 generally well tolerated; no Grade 3+ CRS or GvHD; common Grade 3+ events: thrombocytopenia (69%), neutropenia (56%).
- Preliminary cash, cash equivalents & marketable securities ~$292.5M as of June 30, 2023; enrolling 2L LBCL in dose expansion.

## SEC filing metadata
- accession: 0001619856-23-000087
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/0001619856-23-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/crbu-20230713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000087
- JSON: https://secwatch.observer/filing/0001619856-23-000087.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000087.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported preliminary financial results for the three and six months ended June 30, 2023.
  - Period: the three and six months ended June 30, 2023
  - Result: preliminary results
  source text: Preliminary unaudited cash, cash equivalents, and marketable securities as of June 30, 2023 Caribou Biosciences, Inc. (the “Company”) is providing certain preliminary financial results. On a preliminary unaudited basis, the Company expects its cash, cash equivalents, and marketable securities as of June 30, 2023 to be approximately $292.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000087/0001619856-23-000087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.